Viking Therapeutics, Inc. (VKTX)

$2.95

+0.05 (+1.72%)
Rating:
Recommendation:
Buy
Symbol VKTX
Price $2.95
Beta 1.350
Volume Avg. 0.66M
Market Cap 226.231M
Shares () -
52 Week Range 2.02-7.045
1y Target Est -
DCF Unlevered VKTX DCF ->
DCF Levered VKTX LDCF ->
ROE -31.02% Strong Sell
ROA -32.58% Strong Sell
Operating Margin -
Debt / Equity 9.85% Neutral
P/E -
P/B 1.37 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest VKTX news


Dr. Brian Lian
Healthcare
Biotechnology
NASDAQ Capital Market

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.